MannKind Corporation

NASDAQ:MNKD

Biotechnology

Healthcare
$4.07 -0.51%

-$0.02 today

Market cap
$1.31B
Beta
1.11
P/E (TTM)
-50.3
EPS (TTM)
-$0.08
52W Low $2.23High $6.51

Volume 2.12M

Average 5.73M

MNKD Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

MannKind CorporationNASDAQ: MNKD

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 75.8%

Gross margin was 75.8% in Q1 FY2026, down 1.9 pp from a year earlier. On a trailing-twelve-month basis it was 76.0%, up 1.3 pp year over year. Over 3 fiscal years it widened by 40.1 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
75.8%-2.7 pp QoQ
Last fiscal yearDec 2025
82.5%+9.3 pp YoY
LTMMar 2026
76.0%+1.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.9 pp——
1 year+9.3 pp——
3 years+40.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
82.5%
Year-over-year change
+9.3pp

Gross Margin vs competitors

How MNKD compares with its peers on the latest reported figures

  • MNKD's LTM Mar 2026 gross margin of 76.0% is the 4th highest of the 6 companies compared; the peer median is 77.1%.
  • Its year-over-year change of +1.3 pp is the 2nd highest of 4, against a peer median of +0.6 pp.
  • Over three fiscal years its change of +40.1 pp compares with a peer median of +60.3 pp.
MNKD Competitors Peer median
Gross Margin for MNKD and competitors
Company Period LTM level YoY 3-year change
XERSXeris Biopharma Holdings, Inc.LTM Mar 202681.6% +0.6 pp+2.2 pp
TBPHTheravance Biopharma, Inc.LTM Mar 202680.4% +41.9 pp+118.3 pp
SPRYARS Pharmaceuticals, Inc.LTM Mar 202677.1% -7.5 pp+1276.7 pp
MNKDMannKind CorporationLTM Mar 202676.0% +1.3 pp+40.1 pp
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202637.1% ——
ORMPOramed Pharmaceuticals Inc.FY20250.7% —-99.4 pp
AVLNAvalyn Pharma Inc. Common Stock—— ——
Peer median (excluding MNKD) 77.1%+0.6 pp+60.3 pp

Competitors are the stored peer set for MNKD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.44M99.77M198.96M285.5M348.97M
Cost of Revenue38.86M57.5M62.77M76.6M61.16M
Gross Profit36.59M42.27M136.19M208.9M287.81M
Gross Margin48.5%42.4%68.5%73.2%82.5%
Research & Development12.31M19.72M31.28M45.89M66.35M
Selling, General & Admin77.42M91.47M94.31M94.33M144.14M
Operating Expenses83.61M106.38M127.51M136.32M249.01M
Depreciation & Amortization3.24M6.31M4.54M8.97M12.28M
EBITDA(61.11M)(56.32M)15.13M77.47M27.52M
EBITDA Margin-81.0%-56.4%7.6%27.1%7.9%
Operating Income(47.02M)(64.11M)8.68M72.59M38.8M
Operating Margin-62.3%-64.3%4.4%25.4%11.1%
Interest Income112K2.51M6.15M12.62M0
Interest Expense16.58M24.77M25.16M37.98M13.83M
Other Income / Expenses(33.9M)(23.29M)(19.06M)(42.07M)(37.39M)
Income Before Tax(80.93M)(87.4M)(10.38M)30.52M1.41M
Pre-Tax Margin-107.3%-87.6%-5.2%10.7%0.4%
Income Tax Expense001.56M2.93M(4.46M)
Net Income(80.93M)(87.4M)(11.94M)27.59M5.86M
Net Margin-107.3%-87.6%-6.0%9.7%1.7%
EPS (Basic)(0.37)(0.44)(0.04)0.100.02
EPS (Diluted)(0.37)(0.44)(0.04)0.100.02
Weighted Avg Shares249.24M257.09M267.01M274.42M305.64M
Weighted Avg Shares (Diluted)249.24M257.09M267.01M283.84M314.11M

MannKind Corporation

NASDAQ:MNKD

Intrinsic Alpha fair value

Locked

Current Price

$4.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.